ArticleCancer discovery2025

Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers.

Birgit Wilding et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.